Shionogi & Co.,Ltd. Logo

Shionogi & Co.,Ltd.

A research-driven pharmaceutical firm creating drugs, diagnostics, and devices for global health.

4507 | T

Overview

Corporate Details

ISIN(s):
JP3347200002
LEI:
Country:
Japan
Address:
大阪市中央区道修町3丁目1番8号
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Shionogi & Co., Ltd. is a research-driven pharmaceutical company focused on the discovery, development, manufacturing, and marketing of pharmaceuticals, diagnostic reagents, and medical devices. With a history of over 140 years, the company is dedicated to creating innovative products and services that deliver value to patients and society globally. As a drug discovery-based organization, Shionogi leverages its robust research and development pipeline to address unmet medical needs and contribute to the health of people worldwide.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-07 03:07
Registration Form
確認書
Japanese 8.9 KB
2025-11-07 03:05
Interim Report
半期報告書-第161期(2025/04/01-2026/03/31)
Japanese 327.3 KB
2025-09-25 08:53
M&A Activity
訂正臨時報告書
Japanese 48.0 KB
2025-06-19 09:24
Post-Annual General Meeting Information
臨時報告書
Japanese 30.7 KB
2025-06-19 09:14
Governance Information
内部統制報告書-第160期(2024/04/01-2025/03/31)
Japanese 30.2 KB
2025-06-19 09:12
Registration Form
確認書
Japanese 8.9 KB
2025-06-19 09:10
Annual Report
有価証券報告書-第160期(2024/04/01-2025/03/31)
Japanese 2.5 MB
2025-06-19 08:07
M&A Activity
公開買付報告書
Japanese 41.6 KB
2025-06-19 06:40
Major Shareholding Notification
大量保有報告書
Japanese 61.0 KB
2025-06-18 08:49
Share Issue/Capital Change
臨時報告書
Japanese 41.9 KB
2025-06-04 08:39
M&A Activity
訂正公開買付届出書
Japanese 258.4 KB
2025-05-28 08:38
M&A Activity
訂正公開買付届出書
Japanese 262.0 KB
2025-05-08 05:52
M&A Activity
公開買付届出書
Japanese 530.2 KB
2025-05-07 09:12
M&A Activity
臨時報告書
Japanese 50.3 KB
2024-11-08 02:44
Interim Report
確認書
Japanese 9.0 KB

Automate Your Workflow. Get a real-time feed of all Shionogi & Co.,Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Shionogi & Co.,Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Shionogi & Co.,Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Foghorn Therapeutics Inc. Logo
Pioneering medicines targeting the chromatin regulatory system to treat genetically defined cancers.
United States of America
FHTX
Formycon AG Logo
Develops cost-effective biosimilars for ophthalmology, immunology, and other chronic diseases.
Germany
FYB
Fortress Biotech, Inc. Logo
Acquires, develops, and commercializes drugs for oncology, gene therapy, and rare diseases.
United States of America
FBIO
FRACTYL HEALTH, INC. Logo
Developing gut-targeted endoscopic and gene therapies for obesity and type 2 diabetes.
United States of America
GUTS
Friulchem Logo
CDMO for animal health, providing vet pharma & supplement solutions for pets and livestock.
Italy
FCM
Fuji Pharma Co.,Ltd. Logo
Specializes in hormone medicines for ob/gyn, injectables, and contract manufacturing.
Japan
4554
Fulcrum Therapeutics, Inc. Logo
Develops gene-modulating small molecule drugs for rare, genetically defined diseases.
United States of America
FULC
Fuso Pharmaceutical Industries,Ltd. Logo
Manufactures essential pharmaceuticals like dialysis drugs, infusions, and injections for healthcare.
Japan
4538
FutureChem Co., Ltd. Logo
Develops radiopharmaceuticals & diagnostic agents for cancer, Alzheimer's, and Parkinson's disease.
South Korea
220100
Future Medicine  Co., Ltd. Logo
Clinical-stage biopharma developing novel synthetic drugs for inflammation, fibrosis, and oncology.
South Korea
341170

Talk to a Data Expert

Have a question? We'll get back to you promptly.